ADL5945 0.25 mg
ADL5945 0.25 mg is a pharmaceutical drug with 2 clinical trials. Historical success rate of 100.0%.
Registry-listed formulations
This catalogue entry has no confirmed scientific concept.
Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.
2 source entries across 2 studies. This list may not include all unresolved or historical entries.
- ADL5945 0.25 mgRegistry intervention
Linked study entry; product equivalence not established
View study and source - ADL5945 0.25 mgRegistry intervention
Linked study entry; product equivalence not established
View study and source
Success Metrics
Based on 2 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
2
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
2 of 2 finished
0.0%
0 ended early
0
trials recruiting
2
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Evaluation of the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
Clinical Trials (2)
Evaluation of the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
All 2 trials loaded
Drug Details
- Intervention Type
- Drug
- Total Trials
- 2